Breaking

Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect Program Eli Lilly's Legal Victory Over Noom's GLP-1 Claims BBSW AI Solution Event: Daily Roundup

🇺🇸 Search Americas

Global entity results · articles filtered to FDA

24 intelligence results for “gastroesophageal junction adenocarcinoma”

11 trials · 12 pipelines · 1 articles

🇺🇸 Americas articles · global entities

Top match · Trial

SOX Chemotherapy NCT07072351 View profile →

Iparomlimab and Tuvonralimab Injection in combination with TFOX NCT07400315
Compare
5-Fluorouracil (5-FU) NCT03281369
Compare
SOX Chemotherapy NCT07072351
Compare
SSGJ-706+XELOX NCT07233850
Compare
Iparomlimab and Tuvonralimab combined with lenvatinib and SOX NCT07151209
Compare

All results

Trials (11)

Iparomlimab and Tuvonralimab Injection in combination with TFOX — NCT07400315
5-Fluorouracil (5-FU) — NCT03281369
SOX Chemotherapy — NCT07072351
SSGJ-706+XELOX — NCT07233850
Iparomlimab and Tuvonralimab combined with lenvatinib and SOX — NCT07151209
XELOX combined with Fruquintinib and Sintilimab — NCT06091423
Anti-PD-1 antibody — NCT04098796
A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12) — 2024-511116-25-00
-, IRINOTECAN , PARACETAMOL , -, -, PACLITAXEL , TRIFLURIDINE, COMBINATIONS, MK-2870, DOCETAXEL — 2023-505423-31-00
OXALIPLATIN, AZD0901, CAPECITABINE, FLUOROURACIL, AZD7789, volrustomig, CAPECITABINE, CALCIUM FOLINATE, Rilvegostomig — 2024-510977-27-00
INFLIXIMAB, FOLINIC ACID, IMFINZI 50 mg/mL concentrate for solution for infusion., DOCETAXEL, PLACEBO, OXALIPLATIN, FLUOROURACIL, MYCOPHENOLATE MOFETIL — 2023-507338-26-00

Pipelines (12)

Articles (1)

FDA approves Vyloy for HER2-negative gastric and GEJ cancer — FDA